Denali Therapeutics Inc (DNLI)
20.00
-0.13
(-0.65%)
USD |
NASDAQ |
May 21, 16:00
20.17
+0.17
(+0.85%)
After-Hours: 20:00
Denali Therapeutics Cash from Financing (Quarterly): 500.28M for March 31, 2024
Cash from Financing (Quarterly) Chart
Historical Cash from Financing (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 500.28M |
| December 31, 2023 | 4.705M |
| September 30, 2023 | 2.492M |
| June 30, 2023 | 9.019M |
| March 31, 2023 | 1.604M |
| December 31, 2022 | 299.65M |
| September 30, 2022 | 5.154M |
| June 30, 2022 | 4.402M |
| March 31, 2022 | 1.463M |
| December 31, 2021 | 5.168M |
| September 30, 2021 | 3.315M |
| June 30, 2021 | 7.043M |
| March 31, 2021 | 3.822M |
| December 31, 2020 | 9.522M |
| September 30, 2020 | 425.90M |
| Date | Value |
|---|---|
| June 30, 2020 | 3.415M |
| March 31, 2020 | 195.91M |
| December 31, 2019 | 2.034M |
| September 30, 2019 | 0.679M |
| June 30, 2019 | 2.569M |
| March 31, 2019 | 0.908M |
| December 31, 2018 | 1.69M |
| September 30, 2018 | 0.658M |
| June 30, 2018 | 1.432M |
| March 31, 2018 | 93.24M |
| December 31, 2017 | 295.59M |
| September 30, 2017 | 0.357M |
| June 30, 2017 | 0.051M |
| March 31, 2017 | 0.324M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (Quarterly) Range, Past 5 Years
0.679M
Minimum
Sep 2019
500.28M
Maximum
Mar 2024
74.41M
Average
4.554M
Median
Cash from Financing (Quarterly) Benchmarks
| Halozyme Therapeutics Inc | -0.489M |
| AIM ImmunoTech Inc | 2.829M |
| Perspective Therapeutics Inc | 166.33M |
| Protalix BioTherapeutics Inc | 0.00 |
| Armata Pharmaceuticals Inc | 34.93M |
Cash from Financing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -113.62M |
| Cash from Investing (Quarterly) | -453.19M |
| Free Cash Flow | -425.11M |
| Free Cash Flow Per Share (Quarterly) | -0.7749 |
| Free Cash Flow Yield | -15.02% |